Fact or Fiction – FDA Has a Policy on Social Media?

J0406535This, apparently, is a stampede in progress….

Today the Post ran a story in its Health Section that had the headline "Drug Firms Jockey for Space Online" and when the story print continuity breaks and carries on to a subsequent page, the headline is "Drugmakers Seeking a Niche Flock to Online Social Media."  Emphasis my own.    

Flock?  Flock?  FLOCK?  The only way you could use the term "flock" in connection with pharmaceutical firms and social media is to say that companies are a scared flock of geese.  And they are frightened because they are regulated by an agency at FDA – DDMAC – which has a fundamental lack of understanding of how people use the Internet for healthcare and therefore does not understand how to regulate it.  The result has been regulatory action taken against companies where the rules are unclear and what seems clear one minute is completely unclear in the next.  

How many minutes in a video or Webcast before you have to mention the risk information associated with a drug?  If you mention a benefit, how much time do you have to mention the risk? Know the answer?   No, no one does.  Apparently DDMAC knew, but didn't tell anyone and the fact that no one knew of such a policy didn't stop DDMAC from issuing a warning letter to a Johnson & Johnson this month for violating that unknown rule.  According to the Warning Letter, the video was six minutes long with the risk information bundled at the seventh minute.  Would you have guessed that to be ok?  On a print ad, the risk information is at the end of a multi-page ad (and no one reads it).  What would the difference be?  No one knows, and DDMAC apparently makes this stuff up as they go along.   That is the kind of Whack-a-Mole game DDMAC plays.  We won't tell you what is off limits, until you do it and then WHACK!

Can a company respond to a request for information in a chat room?  When do companies have to report potential adverse events seen perceived in social media?  If a company makes a comment or entry on another Web site and leaves their own Web site information (as everyone does) have they tripped a regulatory wire?  How long into a YouTube video before a company has to mention risk?  Is it a minute, is it two – it certainly isn't six we have learned.  

Does risk information need to be included in a search engine ad that names the drug and what it is for when the placement of the risk information is no differently handled than in a print ad?  Years went by before DDMAC answered that one and apparently the answer was yes.  This, despite the fact that anyone who understands how the Internet is used would know that if a patient is interested in the drug mention, they will click on the link and land on the page with the risk information on it.

So many unanswered questions about the innumerable nuances of social media and the Internet, and an agency that keeps mum about the rules.  What is dysfunctional in that?

That is what was so shocking about the Post article was that its headlines imply this stampede to social media to promote drugs.  In fact, compared to other industries not hobbled by an ineffective regulatory body, the offerings made by pharma in the social media space have been nothing short of anemic, uncoordinated and lacking in sophistication.   And the number of companies actually doing anything at all out of the number of companies that actually exist is miniscule.  Anyone looking at the comprehensive forest would see that there are very few trees within it.

And that was what was so amazing about the statement from the FDA in this article.  Here it is:

"If drug companies or others working on behalf of drug companies wish to promote [their products] using social media tools, FDFA would evaluate the resulting messages as to whether they comply with the applicable laws and regulations.  our laws and regulations don't restrict thte channels that prescription drug companies choose to use for disseminating product promotional messages."
That is the same line they fed me during my podcast with DDMAC in March which turned out to be inaccurate when they issued the 14 untitled letters on search engine ads.  They are still sticking to their story – but take a whole dose of caveat emptor if you want to rely on it.

J0400760 Because when formulating a social media endeavor, which pharma companies should be doing, be aware it is a Wild West venture – anything goes.  Apparently the Post thinks you might get caught up in a stampede, but in reality, it is much more likely some cowboy at DDMAC might mistake you for a mole.  
Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
This entry was posted in New and Social Media. Bookmark the permalink.

10 Responses to Fact or Fiction – FDA Has a Policy on Social Media?

Comments are closed.